Insight

Jun 20, 2024, 10:10

Date of improved response rates in mantle cell lymphoma patients

MD Anderson Cancer Center shared on LinkedIn:

“Adding the BTK inhibitor acalabrutinib to chemoimmunotherapy shows improved response rates in mantle cell lymphoma patients, according to primary data presented by our Dr Michael Wang at the 2024 European Hematology Association Annual General Meeting.

See more research presented by our experts at EHA2024.”

Source: MD Anderson Cancer Center/LinkedIn

2024 European Hematology Association Annual General Meeting cancer chemoimmunotherapy EHA2024 EHA24 European Hematology Association mantle cell lymphoma MD Anderson Cancer Center Michael Wang OncoDaily Oncology

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage